On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
On February 1, 2016, there was a commercial launch of the generic version of imatinib mesylate (Gleevec) which is approved for CML patients by the FDA. As the first to file for generic marketing [...]
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.
A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]
You may have noticed a new look for Gleevec when you refilled your 400-mg prescription.Novartis has introduced new packaging in the U.S. market that includes each individual tablet in a blister pack. This is designed [...]
American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
Saladax Biomedical, a CLIA certified laboratory based in Bethlehem, Pennsylvania, is now providing plasma level testing for imatinib.(Gleevec). Testing is currently free of charge through January 31, 2015, as it is not covered by [...]
A recent clinical trial found that 1 year of adjuvant imatinib was able to increase recurrence-free survival. Keep reading to learn more.
A recent nonrandomized study has shown that imatinib rechallenge impacted the survival rate for patients with advanced or metastatic gastrointestinal stromal tumor (GIST).